دورية أكاديمية
[Impact of Staphylococcus aureus bacteremia in COVID-19 patients].
| العنوان: | [Impact of Staphylococcus aureus bacteremia in COVID-19 patients]. |
|---|---|
| عنوان ترانسليتريتد: | Impacto de la bacteriemia por Staphylococcus aureus en pacientes con COVID-19. |
| المؤلفون: | Espinosa Perez M; María Espinosa Pérez. Hospital Universitario Miguel Servet, Servicio de Medicina Interna. P.º Isabel la Católica, 1-3, 50009 Zaragoza, Spain. mariespiperez@gmail.com., García Fenoll R, Mormeneo Bayo S, Martínez Álvarez RM, Frutos Millán V, Villuendas Usón MC, Palacián Ruiz MP, Arbonés Mainar JM, Martínez Jiménez MC, Ramos Paesa C |
| المصدر: | Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia [Rev Esp Quimioter] 2022 Oct; Vol. 35 (5), pp. 468-474. Date of Electronic Publication: 2022 Jul 22. |
| نوع المنشور: | Journal Article |
| اللغة: | Spanish; Castilian |
| بيانات الدورية: | Publisher: Sociedad Española de Quimioterapia Country of Publication: Spain NLM ID: 9108821 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1988-9518 (Electronic) Linking ISSN: 02143429 NLM ISO Abbreviation: Rev Esp Quimioter Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: [Barcelona] : Sociedad Española de Quimioterapia Original Publication: Barcelona : J.R. Prous, S.A., [1988- |
| مواضيع طبية MeSH: | Bacteremia*/complications , Bacteremia*/epidemiology , COVID-19*/complications , Staphylococcal Infections*/drug therapy , Staphylococcal Infections*/epidemiology, Adult ; Dexamethasone ; Escherichia coli ; Humans ; SARS-CoV-2 ; Staphylococcus aureus |
| مستخلص: | Objective: The disease caused by SARS-CoV-2 (COVID-19) has been a challenge for healthcare professionals since its appearance. Staphylococcus aureus has been described as one of the main pathogens causing bacterial infections in viral pandemics. However, co- infection with S. aureus causing bacteremia in patients with COVID-19 has yet to be well studied. Methods: We performed a e study of S. aureus bacteremia (SAB) at Hospital Miguel Servet (Zaragoza) from March 2020 to February 2021. The clinical characteristics, mortality and risk factors of adults hospitalized patients with BSA associated COVID-19 compared to patients without COVID-19. Results: A total of 95 patients with SAB were identified. 27.3% were positive for SARS-CoV-2. SAB represented 9.9% of bacteremia, being the second agent in frequency after E. coli. Nosocomial bacteremia was more frequent in the group of COVID-19 patients. The most frequent source of BSA in these patients was the respiratory source (26.9% vs 0%; P<0.001) followed by the skin (15.5% vs 15.9%; P=1). The development of sepsis was more frequent in COVID-19 patients (61,5% vs 7,8%; P=0,336) and among them, who received dexamethasone at doses > 6 mg/day (62.5% vs. 37.5%, P<0.05). Conclusions: Our data suggest that BSA has a negative impact on the evolution of patients with COVID-19. However, further and preferably prospective studies are required to obtain solid data on the impact of BSA on coronavirus patients. (©The Author 2022. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).) |
| References: | Clin Microbiol Infect. 2013 May;19(5):465-71. (PMID: 22616816) Viruses. 2021 Oct 20;13(11):. (PMID: 34834917) Front Microbiol. 2017 Jun 23;8:1041. (PMID: 28690590) Clin Microbiol Infect. 2021 Jan;27(1):83-88. (PMID: 32745596) Clin Infect Dis. 2020 Dec 3;71(9):2459-2468. (PMID: 32358954) IUBMB Life. 2020 Oct;72(10):2097-2111. (PMID: 32770825) Med Intensiva (Engl Ed). 2021 Nov;45(8):485-500. (PMID: 34475008) Open Forum Infect Dis. 2020 Nov 12;7(11):ofaa518. (PMID: 33269299) Clin Infect Dis. 2018 Aug 31;67(6):e1-e94. (PMID: 29955859) Enferm Infecc Microbiol Clin (Engl Ed). 2021 Feb 11;:. (PMID: 33663873) Enferm Infecc Microbiol Clin (Engl Ed). 2020 Dec;38(10):489-497. (PMID: 32169398) Clin Infect Dis. 2013 Nov;57(9):1225-33. (PMID: 23929889) J Infect. 2014 Jul;69(1):51-9. (PMID: 24576825) Ann Ist Super Sanita. 2020 Jul-Sep;56(3):359-364. (PMID: 32959802) Br J Clin Pharmacol. 2021 Oct;87(10):3766-3775. (PMID: 33608891) Emerg Infect Dis. 2019 May;25(5):. (PMID: 31002300) Clin Microbiol Infect. 2021 Feb;27(2):283.e9-283.e16. (PMID: 32470569) Rev Clin Esp (Barc). 2020 Nov;220(8):480-494. (PMID: 32762922) PLoS One. 2021 May 6;16(5):e0251170. (PMID: 33956882) |
| فهرسة مساهمة: | Keywords: COVID-19; Staphylococcus aureus; bacteremia; mortality |
| المشرفين على المادة: | 7S5I7G3JQL (Dexamethasone) |
| تواريخ الأحداث: | Date Created: 20220722 Date Completed: 20221003 Latest Revision: 20240905 |
| رمز التحديث: | 20240905 |
| مُعرف محوري في PubMed: | PMC9548065 |
| DOI: | 10.37201/req/022.2022 |
| PMID: | 35866373 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1988-9518 |
|---|---|
| DOI: | 10.37201/req/022.2022 |